Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Is Tucatinib as cardiotoxic as other anti HER2 agents?
Related Questions
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
What is your treatment approach in a male with ER+ Her2+ metastatic breast cancer who received TCHP but developed irreversible cardiomyopathy?
Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?
How do you treat metastatic breast cancer which is HR positive, Her2 negative with PIK3CA+ and high tumor mutational burden (>10) who progressed after prior ET+CDK 4/6 and PIK3CA inhibitor therapy?
How do you sequence therapy in metastatic ER+ HER2 low with everolimus/endocrine therapy versus fam-trastuzumab deruxtecan after progression on CDK4/6 inhibitor?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
What are your top takeaways from ESMO 2023?
